← Eichor
Study identifier: NCT06730438 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Transcranial Pulse Stimulation. a Potential Treatment for Early Dementia

Condition: Alzheimer Disease  ·  Sponsor: Francesca Pistoia

PhaseNA
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Alzheimer's Disease (AD) is characterized by the absence of treatments to slow, stop, or reverse its course, with patients finally losing cognitive functions, skills and independence. It is a chronic degenerative disease with high social and medical burden worldwide: AD ranked third among neurological disorders in terms of disability-adjusted life years (DALY) rates. The primary aim of the research protocol is to improve care for patients with AD, by implementing, with an innovative method, the currently available repertoire of neuromodulation techniques. For this aim, we will investigate whether Transcranial Pulse Stimulation (TPS) may induce cognitive improvement in patients with an early stage of dementia.

This description comes directly from the study's public registry record.

Talk to the study team

Francesca Pistoia, MD, PhD  ·  +39862368657  ·  francesca.pistoia@univaq.it

Always discuss trial participation with your own doctor first.

Locations (2)

San Salvatore HospitalL’Aquila, Italy, ItalyRecruiting
San Salvatore HospitalL’Aquila, Italy, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06730438